Cardiovascular considerations with use of psychoactive medications

American Journal of Therapeutics

Volumn 3, Issue 6, 1996, Pages 454-467

  Frishman, William H ^a   Nurenberg, Michael ^a   Spiegel, Adam ^a  

^a NONE

Author keywords

adverse drug reactions; cardiovascular effects; psychoactive medication

Indexed keywords

AMINOKETONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIBENZOXAZEPINE DERIVATIVE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PERPHENAZINE; PHENETHYLAMINE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TIANEPTINE; TIOTIXENE; TRANQUILIZER; TRIAZOLOPYRIDAZINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030017522     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199606000-00009     Document Type: Review

References (90)

1. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. In: The Pharmacological Basis of Therapeutics (Eds. Molinoff PB, Ruddon RW), McGraw-Hill, New York, NY, 1996, pp. 399-459.
2. Kaplan HI, Sadock BJ, Grebb JA: Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences, Clinical Psychiatry, 7th ed., Williams & Wilkins, Baltimore, 1994, pp. 511, 548, 932, 940-954, 971, 972, 974, 978, 1002, 1003, 1085.
3. Goulet JP, Perysse R, Turcotte JY: Contraindications to vasoconstrictors in dentistry: Part III. Oral Surg Oral Med Oral Pathol 1992;74:692-697.
4. Risch SC, Groom GP, Janowsky DS: Interfaces of psychopharmacology and cardiology: Part 2. J Clin Psychiatr 1981;42(2):47-54.
5. Raehl CL, Patel AK, LeRoy M: Drug induced Torsade de Pointes. Clin Pharmacol 1985;4:675-690.
6. Meltzer HY: New drugs for the treatment of schizophrenia. Psych Clinics North Am 1993;16(2):365-385.
7. Ritton A, Heel RC: Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990;40(5):722-747.
8. Meltzer HY, Gudelsky GA: Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneim Forsch 1992;42(2A):268-272.
9. Gerlach J, Hansen L: Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatr 1992; 17(Suppl):34-37.
10. Farde L, Nordstrom AL: PET analysis indicates atypical central dopamine receptor occupancy in clozapinetreated patients. Br J Psychiatr 1992;17(Suppl):30-33.
11. Meltzer HY: The importance of serotonin-dopamine interaction in the action of clozapine. Br J Psychiatr 1992;17:22-29.
12. Kane JM: Schizophrenia. N Engl J Med 1996;334: 34-11.
13. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM: Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatr 1992;17(Suppl):12-16.
14. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
15. Yunis JJ, Lieberman J, Yunis EJ: Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 1992;7(Suppl):7-9.
16. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatr 1990;47:945-948.
17. Testani M: Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatr 1994;55:497-498.
18. Clardy J, Gale RH: Mortality risk and clozapine (letter to the editor). Am J Psychiatr 1995;152(4):651.
19. Claus A, Bollen J, DeCuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85(4):295-305.
20. Owens DG: Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatr 1994;55(Suppl): 29-35.
21. McEvoy JP: Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatr 1994;55(Suppl):18-21.
22. Chouinard G, Arnott W: Clinical review of risperidone. Can J Psychiatr 1993;38(Suppl 3):S89-S95.
23. Schooler NR: Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatr 1994;55(Suppl):22-28.
24. Lindstrom E, von Knorring L: Changes in single symptoms and separate factors in the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatr 1994;27(3):108-113.
25. Heinrich K, Klieser E, Lehman E, Kinzler E, Hruschka H: Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatr 1994;18:129-137.
26. Brown K, Levy H, Brenner C, Leffler S, Hamburg EL: Overdose of risperidone. Ann Emerg Med 1993;22:1908-1910.
27. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB: Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995;35:730-738.
28. Gerlach J: New antipsychotics: classification, efficacy and adverse effects. Schiz Bull 1991;17(2):289-309.
29. Frasure-Smith N, Lesperance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
30. Burrows GD, Norman TR, Dennerstein L, Davies BM: Antidepressant therapy: benefits and risks in perspective. Acta Scand Psychiatr 1985;72(Suppl 320):43-47.
31. Coccaro EF, Siever L: Second generation antidepressants: a comparative review. J Clin Pharmacol 1985;25:241-260.
32. Risch SC, Groom GP, Janowsky DS: Interfaces of psychopharmacology and cardiology: Part I. J Clin Psychiatr 1981;42:23-30.
33. DaPrada M, Zurcher G, Wuthrich I, Haefely WE: On tyramine food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transmitters 1988;26(Suppl): 31-56.
34. Fallen B, Foote B, Walsh BT, Roose SP: "Spontaneous" hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatr 1988;49:163-165.
35. Chutka DS: Cardiovascular effects of antidepressants: recognition and control. Geriatrics 1990;45:55-67.
36. Halper JP, Mann J: Cardiovascular effects of antidepressant medications. Br J Psychiatr 1988;153(Suppl 3):87-98.
37. Burrows GD, Norman TR, Dennerstein L, Davies BM: Antidepressant therapy: benefits and risks in perspective. Acta Scand Psychiatr 1985;72(Suppl 320):43-47.
38. Glassman AH, Preud'homme XA: Review of cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatr 1993;54(Suppl 2):16-22.
39. Herrman HC, Kaplan LM, Bierer BE: QT prolongation and Torsades de Pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983;51:904-906.
40. Glassman AH: Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984;35:503-511.
41. Stoudemire A, Atkinson P: Use of cyclic antidepressants in patients with cardiac conduction disturbances. Gen Hosp Psychiatr 1988;10:389-397.
42. Martyn R, Somberg JC, Kerin NZ: Proarrhythmia of nonantiarrhythmic drugs. Am Heart J 1993;126:201-205.
43. Ware JC, Rose FV, McBrayer RH: The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994;17:544-550.
44. Andrews JM, Nemeroff CB: Contemporary management of depression. Am J Med 1994;97(6A):24S-32S.
45. Dopheide JA, Stimmel GL, Yi DD: Focus on nefazodone: a serotonergic drug for major depression. Hosp Formul 1995;30:205-212.
46. Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor IE, Chaiken PC, Uderman HD: Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-738.
47. Akiskal HS: The temperamental borders of affective disorders. Acta Psychiatr Scand 1994;379:32-37.
48. Akiskal HS: Dysthymic and cyclothymic depressions: therapeutic considerations. J Clin Psychiatr 1994;55(Suppl): 46-52.
49. Asberg M, Matensson B: Serotonin selective antidepressant drugs: past, present and future. Clin Neuropharmacol 1993;16(Suppl 3):S32-S44.
50. Grimsley SR, Jann MW: Paroxetine, sertraline, and fluvoxamine: new selective serotonin inhibitors. Clin Pharmacol 1992;11:930-957.
51. Rickels S, Schweizer E: Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatr 1990;51(Suppl 2):9-12.
52. Leonard BE: The comparative pharmacology of new antidepressants. J Clin Psychiatr 1993;54(Suppl):3-17.
53. Peet M: Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatr 1994;164:549-550.
54. Hyttel J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl):19-26.
55. Sternback H: The serotonin syndrome. Am J Psychiatr 1991;148:705-713.
56. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cy tochrome P4501A2. Biochem Pharmacol 1993;45(6):1211-1214.
57. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ: Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatr 1994;55:301-305.
58. Schweizer E, Feighner J, Mandos LA, Rickels K: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatr 1994;55:104-108.
59. Khan A, Fabre LF, Rudolph R: Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27(2):141-144.
60. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
61. Wilde MI, Benfield P: Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995;49:411-439.
62. Guelfi JD, Dulcire C, LeMoine P, Tafani A: Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice. Neuropsychobiology 1992;25: 140-148.
63. Rickels K: Buspirone in clinical practice. J Clin Psychiatr 1990;51(Suppl):51-54.
64. Tunnicliff G: Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991;69:149-156.
65. Napoliello MJ, Domantay AG: Buspirone: a worldwide update. Br J Psychiatr 1991;12(Suppl):40-44.
66. Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB: Treatment of generalized anxiety disorder: preliminary, clinical experience with buspirone. J Clin Psychiatr 1990;51(Suppl):31-39.
67. Balster RL: Abuse potential of buspirone and related drugs. J Clin Psychopharmacol 1990;10(3, Suppl):31s-37s.
68. Lucki I: Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatr 1991;52(Suppl): 24-31.
69. Frishman WH, Razin A, Swenciones C, Sonnenblick EH: Update: β-adrenergic blockade in anxiety states. Cardiovasc Rev Rep 1992;13(2):8-31.
70. Gelenberg AJ, Hopkins HS: Report on efficacy of treatments for bipolar disorder. Psychopharmacol Bull 1993; 29(4):447-156.
71. Murray JB: New applications of lithium therapy. J Psychiatr 1990;124:55-73.
72. Goodwin FK, Jamison KR: Manic Depressive Illness, Oxford University Press, New York, 1990, pp. 603-611.
73. Coxhead N, Silverstone T, Cookson J: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-118.
74. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF: Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatr 1991;48:915-921.
75. Post RM: Non-lithium treatment for bipolar disorder. J Clin Psychiatr 1990;51(Suppl):9-19.
76. Tohen M, Castillo J, Pope HG Jr, Herbstein J: Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14:67-70.
77. Joffe RT: Valproate in bipolar disorder: the Canadian perspective. Can J Psychiatr 1993;38(3, Suppl 2):S46-S50.
78. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O: Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-1429.
79. Kasarskis EJ, Kuo CS, Berger R, Nelson KR: Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992;152:186-191.
80. el-Mallakh RS, Jaziri WA: Calcium channel blockers in affective illness: role of sodium-calcium exchange. J Clin Psychopharmacol 1990;10:203-206.
81. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB: Preliminary controlled trial of nimodipine in ultrarapid cycling affective dysregulation. Psychiatr Res 1993; 49(3):257-272.
82. Dobovsky SL: Calcium antagonists in manic-depressive illness. Neuropsychobiology 1993;27:184-192.
83. Jenike MA, Baer L, Greist JH: Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990;10:122-124.
84. Kelly NW, Myers CW: Clomipramine: a tricyclic antidepressant effective in obsessive-compulsive disorder. Ann Pharmacother 1990;24:739-744.
85. Wilde MI, Plosker GL, Benfield P: Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46(5):895-924.
86. Allison TG, Williams DE, Miller TD, Patten CA, Bailey KR, Squires RW, Gau GT: Medical and economic costs of psychologic distress in patients with coronary artery disease. Mayo Clinic Proc 1995;70:734-742.
87. Pasternak RC: Psychiatrogic factors and course after myocardial infarction: maturing of a risk factor. Mayo Clinic Proc 1995;70:809-810.
88. Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact on 6-month survival. J Am Med Assoc 1993;270:1819-1825.
89. Kawachi I, Graham A, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC: Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994;89:1992-1997.
90. Rotmensch HH, Terdiman R, Galler E, Laniado S: Hemodynamic effects of chlorpromazine in patients with acute myocardial infarction and left ventricular failure chest. 1977;72:623-627.